KalVista Pharmaceuticals (NASDAQ:KALV) announces that its option agreement with Merck (NYSE:MRK)
related to KVD001, its candidate for the potential treatment of
diabetic macular edema (DME), and future oral DME molecules has expired.
Merck had the option to in-license KVD001 and
future oral plasma kallikrein inhibitor programs for DME via paying a
non-refundable $37M fee to KalVista who now has no obligations to Merck
and retains full ownership of all assets.
https://seekingalpha.com/news/3540308-merck-passes-on-kalvista-dme-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.